References
- Puy H, Gouya L, Deybach J-C. Porphyrias. Lancet. 2010;375:924–937.
- Tollali G, Nielsen EW, Brekke OL. [Acute intermittent porphyria]. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin. ny Raekke. 2002;122:1102–1105.
- Hift RJ, Thunell S, Brun A. Drugs in porphyria: from observation to a modern algorithm-based system for the prediction of porphyrogenicity. Pharmacol Ther. 2011;132:158–169.
- Andersson C, Thunell S, Floderus Y, et al. Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. J Intern Med. 1995;237:301–308.
- Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem. 2006; 52:650–656.
- Schulenburg-Brand D, Gardiner T, Guppy S, et al. An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Reports. 2017;36:99–107.
- Westgard J. Desirable Biological Variation Database specifications; 2014 [cited 2018]. Available from: https://www.westgard.com/biodatabase1.htm
- Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201–214.